% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, AŞ Message Board

  • kyjellie kyjellie Feb 22, 2013 10:49 AM Flag

    Good news bad news

    Bad first. A insider sold 50,000 shares.

    Good news:

    AT13387 looking over this drug in a NSCLC trial. I believe there are some important things to know about this trial. First how many locations they are testing this drug. It looks like 43 locations. That is a very large number of clinics participating. But what I also looked at is the Changes made in this trial. We learned from SGI-110 that they increased the pt count a while back and that was a good sign. Now what changes have been made in this NSCLC trial. Numerous and they changed originally what the trial would need to these new changes. The big ones that stand out, originally 7 months would be needed to compare objective response rates by Recist...the change is now 18 Months. The longer the my opinion.

    We had several changes from 7 month to 18 months to #$%$ the safety of at13387 alon and in comparison.

    I feel these are positive moves. Survival is the key to approval in NSCLC. Some of these moves are 10 months. However this is a very difficult cancer to get great final results.

    SortNewest  |  Oldest  |  Most Replied Expand all replies